Home LiteratureArticle Details
PMID: 19246616 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Review

Utilizing the molecular gateway: the path to personalized cancer management.

Clinical chemistry ·Vol. 55 ·No. 4 ·2009-04-00 ·Pages 684-97

Overdevest JB, Theodorescu D, Lee JK

Abstract

Personalized medicine is the provision of focused prevention, detection, prognostic, and therapeutic efforts according to an individual's genetic composition. The actualization of personalized medicine will require combining a patient's conventional clinical data with bioinformatics-based molecular-assessment profiles. This synergistic approach offers tangible benefits, such as heightened specificity in the molecular classification of cancer subtypes, improved prognostic accuracy, targeted development of new therapies, novel applications for old therapies, and tailored selection and delivery of chemotherapeutics. Our ability to personalize cancer management is rapidly expanding through biotechnological advances in the postgenomic era. The platforms of genomics, proteomics, single-nucleotide polymorphism profiling and haplotype mapping, high-throughput genomic sequencing, and pharmacogenomics constitute the mechanisms for the molecular assessment of a patient's tumor. The complementary data derived during these assessments is processed through bioinformatics analysis to offer unique insights for linking expression profiles to disease detection, tumor response to chemotherapy, and patient survival. Together, these approaches permit improved physician capacity to assess risk, target therapies, and tailor a chemotherapeutic treatment course. Personalized medicine is poised for rapid growth as the insights provided by new bioinformatics models are integrated with current procedures for assessing and treating cancer patients. Integration of these biological platforms will require refinement of tissue-processing and analysis techniques, particularly in clinical pathology, to overcome obstacles in customizing our ability to treat cancer.

MeSH Terms
Animals Computational Biology Genome, Human/genetics Humans Molecular Diagnostic Techniques/methods Neoplasms/classification,metabolism,pathology,therapy Personal Health Services/methods
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Overdevest Jonathan B
Departments of Molecular Physiology and Biological Physics; and Public Health Sciences, University of Virginia Health Sciences Center, Charlottesville, VA 22908, USA.
Theodorescu Dan
Lee Jae K
References (63)
63 references, click to expand
  1. Protein microarrays and proteomics.
    Nat Genet. 2002 Dec;32 Suppl:526-32 PMID: 12454649
  2. Gene expression signature of primary imatinib-resistant chronic myeloid leukemia patients.
    Leukemia. 2006 Aug;20(8):1400-7 PMID: 16728981
  3. Interlaboratory performance of a microarray-based gene expression test to determine tissue of origin in poorly differentiated and undifferentiated cancers.
    J Mol Diagn. 2008 Jan;10(1):67-77 PMID: 18083688
  4. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer.
    J Clin Oncol. 2004 Jun 15;22(12):2284-93 PMID: 15136595
  5. Cancer statistics, 2008.
    CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 PMID: 18287387
  6. Real-time PCR technology for cancer diagnostics.
    Clin Chem. 2002 Aug;48(8):1178-85 PMID: 12142370
  7. The hallmarks of cancer.
    Cell. 2000 Jan 7;100(1):57-70 PMID: 10647931
  8. Trends in biomarker research for cancer detection.
    Lancet Oncol. 2001 Nov;2(11):698-704 PMID: 11902541
  9. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification.
    J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 PMID: 12509396
  10. Gene expression profiles of multiple breast cancer phenotypes and response to neoadjuvant chemotherapy.
    Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):819-26 PMID: 16467094
  11. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.
    N Engl J Med. 2004 Dec 30;351(27):2817-26 PMID: 15591335
  12. Personalized medicine and proteomics: lessons from non-small cell lung cancer.
    J Proteome Res. 2007 Aug;6(8):2925-35 PMID: 17636986
  13. MicroRNA signature predicts survival and relapse in lung cancer.
    Cancer Cell. 2008 Jan;13(1):48-57 PMID: 18167339
  14. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis.
    Mol Cancer Ther. 2002 Oct;1(12):1035-42 PMID: 12481426
  15. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer.
    N Engl J Med. 2006 Aug 10;355(6):570-80 PMID: 16899777
  16. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling.
    Clin Cancer Res. 2005 Apr 1;11(7):2625-36 PMID: 15814643
  17. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks.
    Nat Rev Drug Discov. 2007 Nov;6(11):871-80 PMID: 17932492
  18. Epigenetics in cancer: implications for early detection and prevention.
    Lancet Oncol. 2002 Dec;3(12):755-63 PMID: 12473517
  19. Protein microarrays: meeting analytical challenges for clinical applications.
    Cancer Cell. 2003 Apr;3(4):317-25 PMID: 12726858
  20. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
    Nature. 2000 Feb 3;403(6769):503-11 PMID: 10676951
  21. Selection bias in gene extraction on the basis of microarray gene-expression data.
    Proc Natl Acad Sci U S A. 2002 May 14;99(10):6562-6 PMID: 11983868
  22. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
    N Engl J Med. 2002 Jun 20;346(25):1937-47 PMID: 12075054
  23. A molecular signature of metastasis in primary solid tumors.
    Nat Genet. 2003 Jan;33(1):49-54 PMID: 12469122
  24. Gene expression profiling predicts clinical outcome of breast cancer.
    Nature. 2002 Jan 31;415(6871):530-6 PMID: 11823860
  25. Cancer genomics.
    Cancer Cell. 2002 Feb;1(1):37-47 PMID: 12086886
  26. CYP450 pharmacogenetics for personalizing cancer therapy.
    Drug Resist Updat. 2008 Jun;11(3):77-98 PMID: 18486526
  27. Sequence-based cancer genomics: progress, lessons and opportunities.
    Nat Rev Genet. 2003 Jun;4(6):409-18 PMID: 12776211
  28. Proteomic applications for the early detection of cancer.
    Nat Rev Cancer. 2003 Apr;3(4):267-75 PMID: 12671665
  29. Mass spectrometry-based proteomics.
    Nature. 2003 Mar 13;422(6928):198-207 PMID: 12634793
  30. Dicer, Drosha, and outcomes in patients with ovarian cancer.
    N Engl J Med. 2008 Dec 18;359(25):2641-50 PMID: 19092150
  31. A pilot study of high-throughput, sequence-based mutational profiling of primary human acute myeloid leukemia cell genomes.
    Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14275-80 PMID: 14614138
  32. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays.
    Nat Clin Pract Oncol. 2006 May;3(5):256-68 PMID: 16683004
  33. Epigenetics in cancer.
    N Engl J Med. 2008 Mar 13;358(11):1148-59 PMID: 18337604
  34. Tumor mRNA expression profiles predict responses to chemotherapy.
    J Clin Oncol. 2007 Oct 1;25(28):4329-36 PMID: 17906194
  35. Molecular portraits of human breast tumours.
    Nature. 2000 Aug 17;406(6797):747-52 PMID: 10963602
  36. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling.
    Cancer Cell. 2002 Mar;1(2):133-43 PMID: 12086872
  37. Next-generation DNA sequencing.
    Nat Biotechnol. 2008 Oct;26(10):1135-45 PMID: 18846087
  38. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.
    Br J Cancer. 2004 Jul 19;91(2):355-8 PMID: 15188009
  39. Genetic testing for cancer risk.
    Science. 1997 Nov 7;278(5340):1050-4 PMID: 9353178
  40. Applying the discovery of the Philadelphia chromosome.
    J Clin Invest. 2007 Aug;117(8):2067-74 PMID: 17671641
  41. Unlocking the archive--gene expression in paraffin-embedded tissue.
    J Pathol. 2001 Sep;195(1):66-71 PMID: 11568892
  42. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies.
    Clin Chem. 2001 Feb;47(2):164-72 PMID: 11159763
  43. Tumor heterogeneity and the biology of cancer invasion and metastasis.
    Cancer Res. 1978 Sep;38(9):2651-60 PMID: 354778
  44. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
    Blood. 2005 Jan 15;105(2):821-6 PMID: 15388585
  45. Genomic signatures to guide the use of chemotherapeutics.
    Nat Med. 2006 Nov;12(11):1294-300 PMID: 17057710
  46. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery.
    Proc Natl Acad Sci U S A. 2007 Aug 7;104(32):13086-91 PMID: 17666531
  47. Emerging molecular markers of cancer.
    Nat Rev Cancer. 2002 Mar;2(3):210-9 PMID: 11990857
  48. DNA microarrays in clinical oncology.
    J Clin Oncol. 2002 Apr 1;20(7):1932-41 PMID: 11919254
  49. Pharmacogenomics: translating functional genomics into rational therapeutics.
    Science. 1999 Oct 15;286(5439):487-91 PMID: 10521338
  50. Application of microarrays to the analysis of gene expression in cancer.
    Clin Chem. 2002 Aug;48(8):1170-7 PMID: 12142369
  51. Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.
    Oncologist. 2007 Apr;12(4):397-405 PMID: 17470682
  52. Targeting targeted therapy.
    N Engl J Med. 2004 May 20;350(21):2191-3 PMID: 15118072
  53. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring.
    Science. 1999 Oct 15;286(5439):531-7 PMID: 10521349
  54. Commercialized multigene predictors of clinical outcome for breast cancer.
    Oncologist. 2008 May;13(5):477-93 PMID: 18515733
  55. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen.
    Cancer Cell. 2004 Jun;5(6):607-16 PMID: 15193263
  56. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    J Clin Oncol. 2007 Feb 10;25(5):517-25 PMID: 17290060
  57. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells.
    Cancer Res. 2007 Feb 15;67(4):1424-9 PMID: 17308079
  58. Circulating microRNAs as stable blood-based markers for cancer detection.
    Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8 PMID: 18663219
  59. Is personalized medicine finally arriving?
    Nat Biotechnol. 2008 May;26(5):509-17 PMID: 18464779
  60. Evaluation and validation of total RNA extraction methods for microRNA expression analyses in formalin-fixed, paraffin-embedded tissues.
    J Mol Diagn. 2008 May;10(3):203-11 PMID: 18403610
  61. The International HapMap Project.
    Nature. 2003 Dec 18;426(6968):789-96 PMID: 14685227
  62. MicroRNA signatures in human cancers.
    Nat Rev Cancer. 2006 Nov;6(11):857-66 PMID: 17060945
  63. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues.
    Proc Natl Acad Sci U S A. 2004 Jun 29;101(26):9740-4 PMID: 15210942
Article Info
Journal
Clinical chemistry
Abbr.
Clin Chem
ISSN
1530-8561
DOI
10.1373/clinchem.2008.118554
Published
2009-04-00
Epub
2009-00-26
Pages
684-97
Language
English
Region
England
NLM ID
9421549
PMCID
PMC4529063
Subset
IM
Grants
NCI NIH HHS · R01 CA075115 · United States
NHLBI NIH HHS · R01 HL081690 · United States
NHLBI NIH HHS · R01HL081690 · United States
NCI NIH HHS · R01 CA075115-12 · United States
NCI NIH HHS · R01CA075115 · United States
PHS HHS · T32A009109 · United States
External Links
PubMed source DOI: 10.1373/clinchem.2008.118554 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2